Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 510 people across three groups: 168 received a placebo (dummy treatment), 166 received a lower dose of tiotropium Respimat (2.5 micrograms), and 176 received a higher dose (5 micrograms). The vast majority of participants finished the trial — around 161, 159, and 169 people respectively in each group. The trial was measuring changes in lung function over 12 weeks, specifically looking at how well participants could breathe out air, using several different breathing tests. The reported data shows the following numbers for the two main measures at week 12. For the first primary measure — how much air participants could forcefully breathe out over one second, averaged across a four-hour window — the placebo group's score changed by −1.74 percentage points from their starting point, while the 2.5 microgram group changed by +1.20 and the 5 microgram group by +1.65 percentage points. For the second primary measure — the same breathing-out test but taken at a single "trough" point (the lowest point before the next dose) — the placebo group changed by −1.44 percentage points, compared with +0.81 for the 2.5 microgram group and +0.78 for the 5 microgram group. The reported data also shows results from several secondary (additional) lung function measures at week 12. For the total amount of air breathed out in one breath (FVC), averaged across four hours, changes were −1.30 for placebo, +0.53 for the lower dose, and +1.81 percentage points for the higher dose. A measure of airflow through the middle part of a breath showed changes of −1.40, +2.78, and +3.94 percentage points respectively. A measure of air trapped in the lungs (RV/TLC ratio) showed very small changes of −0.01, 0.00, and +0.04 percentage points across the three groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 25819269) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Cystic Fibrosis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Both men and women can apply.
- You must have a confirmed diagnosis of Cystic Fibrosis, shown either by a sweat chloride test or by having two identified genetic mutations related to CF.
- Your lung function (measured by a breathing test called FEV1) must be at least 25% of the normal expected value, measured before using an inhaler.
Who may not be able to join:
- You may not be eligible if you have a significant history of allergies or serious allergic reactions.
- You may not be eligible if you are known to be allergic or sensitive to the medication being studied.
- You may not be eligible if you are currently taking part in another clinical trial.
- Women who are pregnant or breastfeeding may not be eligible.
- Women who are able to become pregnant may not be eligible (confirm with trial site).
- You may not be eligible if you have started a new medication for Cystic Fibrosis within the 4 weeks before your screening appointment.
- You may not be eligible if you have a known history of substance misuse or abuse.
- You may not be eligible if you have another serious medical condition beyond Cystic Fibrosis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Boehringer Ingelheim, Boehringer Ingelheim
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent Predicted FEV1 AUC0-4 Response at the End of Week 12; Percent Predicted FEV1 Trough Response at the End of Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.